Rare cancers, Rare hisotogical subtypes of major cancers, Carcinoma of unknown primary
Conditions
Interventions
None listed
Sponsors
National Cancer Center Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients aged 16 years or older at registration. 2) Patients who meet the eligible criteria for the MASTER KEY Registry study (NCCH1612) and have provided a written consent to the MASTER KEY Registry study (NCCH1612). (Enrollment into the MASTER KEY Registry study (NCCH1612) must be done before enrollment into this research study. 3) Patients who provided a written consent to participate in the study (for patients less than 20 years of age, their legally acceptable representative must give consent). For patients who have a will to consent but are physically unable to provide a signature, an allograph by a relative is applicable.
Exclusion criteria
Exclusion criteria: none
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Overall incidence of any genetic alterations(analyzed in all rare cancer patients cohort and in each histopathlological subgroup cohort) 2) Incidence of individual genetic alteration(analyzed in all rare cancer patients cohort and in each histopathlological subgroup cohort) | — |
Secondary
| Measure | Time frame |
|---|---|
| To investigate the congruence of the reported gene alterations from this research study and tissue-based NGS from prior tests, treatment patterns according to each gene alteration, response to treatment, etc. | — |
Countries
Japan
Contacts
Public ContactHitomi Okuma
National Cancer Center Hospital Clinical Trial Management Section, Research Management Division/Department of Breast and Medical Onc
Outcome results
None listed